Skip to main content
Erschienen in: Surgery Today 3/2014

01.03.2014 | Review Article

Treatment strategies for gastric cancer patients with peritoneal metastasis

verfasst von: Motohiro Imano, Kiyotaka Okuno

Erschienen in: Surgery Today | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Although the treatment of gastric cancer improves the clinical outcomes, the survival of gastric cancer patients with peritoneal metastasis is still very poor. Effective drugs against peritoneal metastasis, coupled with new therapeutic modalities, are needed to improve the prognoses of these patients. Paclitaxel and TS-1 are candidate drugs for peritoneal metastasis, and intraperitoneal chemotherapy and targeted therapy are potential new therapeutic modalities. Two phase II studies using TS-1 and intraperitoneal and systemic paclitaxel for gastric cancer patients with peritoneal metastasis showed respectable survival results. In addition, peritoneal metastatic lesions showed high levels of epithelial cellular adhesion molecule (ECAM) and very low levels of human epidermal growth factor receptor 2 (HER2), thus indicating that an anti-ECAM monoclonal antibody, catumaxomab, would be effective against gastric cancer-derived peritoneal metastasis. Although catumaxomab and intraperitoneally administered paclitaxel are not generally used in Japan at present, these treatment strategies might therefore be effectively used in Japan in the near future.
Literatur
1.
Zurück zum Zitat Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993;80(8):1015–8.PubMedCrossRef Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993;80(8):1015–8.PubMedCrossRef
5.
Zurück zum Zitat Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96–107 ([pii] 12086).PubMedCrossRef Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96–107 ([pii] 12086).PubMedCrossRef
6.
Zurück zum Zitat Fujimoto S, Takahashi M, Kobayashi K, Kure M, Mutou T, Masaoka H, Ohkubo H. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis. Oncology. 1993;50(5):338–43.PubMedCrossRef Fujimoto S, Takahashi M, Kobayashi K, Kure M, Mutou T, Masaoka H, Ohkubo H. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis. Oncology. 1993;50(5):338–43.PubMedCrossRef
7.
Zurück zum Zitat Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2000;18(23):4001–3.PubMed Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2000;18(23):4001–3.PubMed
8.
Zurück zum Zitat Fujii M, Kim YH, Satoh T, Hosaka H, T. Kim, Tsuji A, Inokuchi M, Takagane A, Oh SC, Tanabe K, Okuno T, Chin K, Ura T, Lee JI, Kakudo Y, Yamaguchi K, Iijima S, Takeuchi M, Kim H, Nakajima T. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial update. J Clin Oncol 2011;29 (suppl; abstr 4016). Fujii M, Kim YH, Satoh T, Hosaka H, T. Kim, Tsuji A, Inokuchi M, Takagane A, Oh SC, Tanabe K, Okuno T, Chin K, Ura T, Lee JI, Kakudo Y, Yamaguchi K, Iijima S, Takeuchi M, Kim H, Nakajima T. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial update. J Clin Oncol 2011;29 (suppl; abstr 4016).
9.
Zurück zum Zitat Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi Y, Takiuchi H, Nasu J, Nakamura K, Fukuda H, Ohtsu A. Randomized phase III study of 5-fluorouracil continuous infusion (5FU ci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106).escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. J Clin Oncol 2009;27(15s):suppl; abst 4545. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi Y, Takiuchi H, Nasu J, Nakamura K, Fukuda H, Ohtsu A. Randomized phase III study of 5-fluorouracil continuous infusion (5FU ci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106).escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. J Clin Oncol 2009;27(15s):suppl; abst 4545.
10.
Zurück zum Zitat Takiuchi H, H. F, Boku N, Shimada Y, Nasu J, Hamamoto Y, Hironaka S, Yamaguchi K, Takashima A, Ohtsu A. Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). J Clin Oncol 2010;28(15s):suppl; abstr 4052. Takiuchi H, H. F, Boku N, Shimada Y, Nasu J, Hamamoto Y, Hironaka S, Yamaguchi K, Takashima A, Ohtsu A. Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). J Clin Oncol 2010;28(15s):suppl; abstr 4052.
11.
Zurück zum Zitat Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21. doi:10.1016/S1470-2045(08)70035-4.PubMedCrossRef Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21. doi:10.​1016/​S1470-2045(08)70035-4.PubMedCrossRef
12.
Zurück zum Zitat Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-Fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-Fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(5):548–57.PubMedCrossRef Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-Fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-Fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(5):548–57.PubMedCrossRef
14.
Zurück zum Zitat Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Akimasa N. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). Anticancer Res. 2007;27(4C):2667–71.PubMed Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Akimasa N. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). Anticancer Res. 2007;27(4C):2667–71.PubMed
15.
Zurück zum Zitat Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998;9(4):307–10.PubMedCrossRef Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998;9(4):307–10.PubMedCrossRef
16.
17.
Zurück zum Zitat Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, Monden M. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. Oncology. 2003;64(2):176–82 ([pii] 67774).PubMedCrossRef Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, Monden M. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. Oncology. 2003;64(2):176–82 ([pii] 67774).PubMedCrossRef
18.
Zurück zum Zitat Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, Araki K. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 2006;12(9):1412–5.PubMed Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, Araki K. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 2006;12(9):1412–5.PubMed
19.
Zurück zum Zitat Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujinaka T, Furukawa H, Taguchi T. Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology. 2008;74(1–2):37–41. doi:10.1159/000138978.PubMedCrossRef Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujinaka T, Furukawa H, Taguchi T. Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology. 2008;74(1–2):37–41. doi:10.​1159/​000138978.PubMedCrossRef
20.
Zurück zum Zitat Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K, Asao T, Kuwano H. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer. 2006;95(12):1642–7. doi:10.1038/sj.bjc.6603497.PubMedCentralPubMedCrossRef Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K, Asao T, Kuwano H. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer. 2006;95(12):1642–7. doi:10.​1038/​sj.​bjc.​6603497.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Imano M, Peng YF, Itoh T, Nishikawa M, Satou T, Yasuda A, Inoue K, Kato H, Shinkai M, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Furukawa H, Takeyama Y, Okuno K, Shiozaki H. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. Anticancer Res. 2012;32(9):4071–5 ([pii] 32/9/4071).PubMed Imano M, Peng YF, Itoh T, Nishikawa M, Satou T, Yasuda A, Inoue K, Kato H, Shinkai M, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Furukawa H, Takeyama Y, Okuno K, Shiozaki H. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. Anticancer Res. 2012;32(9):4071–5 ([pii] 32/9/4071).PubMed
22.
Zurück zum Zitat Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10(9):1485–91.PubMed Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10(9):1485–91.PubMed
23.
Zurück zum Zitat Imano M, Imamoto H, Itoh T, Satou T, Peng YF, Yasuda A, Kato H, Shiraishi O, Shinkai M, Yasuda T, Takeyama Y, Okuno K, Shiozaki H. Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection. J Surg Oncol. 2012;105(1):43–7. doi:10.1002/jso.22065.PubMedCrossRef Imano M, Imamoto H, Itoh T, Satou T, Peng YF, Yasuda A, Kato H, Shiraishi O, Shinkai M, Yasuda T, Takeyama Y, Okuno K, Shiozaki H. Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection. J Surg Oncol. 2012;105(1):43–7. doi:10.​1002/​jso.​22065.PubMedCrossRef
24.
Zurück zum Zitat Soma D, Kitayama J, Konno T, Ishihara K, Yamada J, Kamei T, Ishigami H, Kaisaki S, Nagawa H. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. Cancer Sci. 2009;100(10):1979–85. doi:10.1111/j.1349-7006.2009.01265.x.PubMedCrossRef Soma D, Kitayama J, Konno T, Ishihara K, Yamada J, Kamei T, Ishigami H, Kaisaki S, Nagawa H. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. Cancer Sci. 2009;100(10):1979–85. doi:10.​1111/​j.​1349-7006.​2009.​01265.​x.PubMedCrossRef
26.
Zurück zum Zitat Imano M, Yasuda A, Itoh T, Satou T, Peng YF, Kato H, Shinkai M, Tsubaki M, Chiba Y, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Okuno K, Furukawa H, Shiozaki H. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg. 2012;. doi:10.1007/s11605-012-2059-3.PubMed Imano M, Yasuda A, Itoh T, Satou T, Peng YF, Kato H, Shinkai M, Tsubaki M, Chiba Y, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Okuno K, Furukawa H, Shiozaki H. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg. 2012;. doi:10.​1007/​s11605-012-2059-3.PubMed
27.
Zurück zum Zitat Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67–70. doi:10.1093/annonc/mdp260.PubMedCrossRef Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67–70. doi:10.​1093/​annonc/​mdp260.PubMedCrossRef
29.
Zurück zum Zitat Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105:38–42. doi:10.1002/jso.22057.PubMedCrossRef Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105:38–42. doi:10.​1002/​jso.​22057.PubMedCrossRef
30.
Zurück zum Zitat Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res. 2003;9(16 Pt 1):5896–901.PubMed Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res. 2003;9(16 Pt 1):5896–901.PubMed
31.
Zurück zum Zitat Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, Fujimura T, Nishimura G, Kayahara M, Ohta T. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 2008;19(5):1305–10.PubMed Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, Fujimura T, Nishimura G, Kayahara M, Ohta T. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 2008;19(5):1305–10.PubMed
32.
Zurück zum Zitat Kodera Y, Imano M, Yoshikawa T, Takahashi N, Tsuburaya A, Miyashita Y, Morita S, Nakao A, Sakamoto J, Sasako M. A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial). Jpn J Clin Oncol. 2011;41(2):283–6. doi:10.1093/jjco/hyq187.PubMedCrossRef Kodera Y, Imano M, Yoshikawa T, Takahashi N, Tsuburaya A, Miyashita Y, Morita S, Nakao A, Sakamoto J, Sasako M. A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial). Jpn J Clin Oncol. 2011;41(2):283–6. doi:10.​1093/​jjco/​hyq187.PubMedCrossRef
33.
Zurück zum Zitat Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. doi:10.1016/S0140-6736(10)61121-X.PubMedCrossRef Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. doi:10.​1016/​S0140-6736(10)61121-X.PubMedCrossRef
34.
Zurück zum Zitat Imano M, Satou T, Itoh T, Yasuda A, Kato H, Shinkai M, Peng YF, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Okuno K, Shiozaki H. Peritoneal metastatic lesions of gastric cancer exhibit low expression of human epidermal growth factor receptor 2. Target Oncol. 2012;. doi:10.1007/s11523-012-0223-z. Imano M, Satou T, Itoh T, Yasuda A, Kato H, Shinkai M, Peng YF, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Okuno K, Shiozaki H. Peritoneal metastatic lesions of gastric cancer exhibit low expression of human epidermal growth factor receptor 2. Target Oncol. 2012;. doi:10.​1007/​s11523-012-0223-z.
35.
Zurück zum Zitat Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20(1):13–24. doi:10.1097/PAI.0b013e31821c821c.PubMedCrossRef Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20(1):13–24. doi:10.​1097/​PAI.​0b013e31821c821c​.PubMedCrossRef
36.
Zurück zum Zitat Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21. doi:10.1002/ijc.25423.PubMedCentralPubMedCrossRef Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21. doi:10.​1002/​ijc.​25423.PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Imano M, Itoh T, Satou T, Yasuda A, Nishiki K, Kato H, Shiraishi O, Peng YF, Shinkai M, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Furkawa H, Okuno K, Shiozaki H. High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer. Target Oncol. 2012;. doi:10.1007/s11523-012-0239-4. Imano M, Itoh T, Satou T, Yasuda A, Nishiki K, Kato H, Shiraishi O, Peng YF, Shinkai M, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Furkawa H, Okuno K, Shiozaki H. High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer. Target Oncol. 2012;. doi:10.​1007/​s11523-012-0239-4.
Metadaten
Titel
Treatment strategies for gastric cancer patients with peritoneal metastasis
verfasst von
Motohiro Imano
Kiyotaka Okuno
Publikationsdatum
01.03.2014
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 3/2014
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-013-0603-8

Weitere Artikel der Ausgabe 3/2014

Surgery Today 3/2014 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.